MEDICOS ROMBACH : revenue, balance sheet and financial ratios

MEDICOS ROMBACH is a French company founded 42 years ago, specialized in the sector Fabrication d'emballages en matières plastiques. Based in ROMBACH-LE-FRANC (68660), this company of category PME shows in 2024 a revenue of 11.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - MEDICOS ROMBACH (SIREN 329957971)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue 11 564 354 € 9 428 131 € 8 856 010 € 8 448 783 € 7 064 496 € 7 931 013 € 8 887 887 € 8 619 780 € 8 532 165 € 8 554 234 €
Net income 2 182 582 € 1 500 374 € 1 037 052 € 1 321 970 € 912 026 € 1 368 709 € 1 718 753 € 1 717 634 € 1 532 967 € 1 408 184 €
EBITDA 2 953 328 € 1 968 517 € 1 377 258 € 1 857 629 € 1 317 036 € 2 194 496 € 2 599 308 € 2 599 703 € 2 228 662 € 2 241 693 €
Net margin 18.9% 15.9% 11.7% 15.6% 12.9% 17.3% 19.3% 19.9% 18.0% 16.5%

Revenue and income statement

In 2024, MEDICOS ROMBACH achieves revenue of 11.6 M€. Revenue is growing positively over 10 years (CAGR: +3.4%). Vs 2023, growth of +23% (9.4 M€ -> 11.6 M€). After deducting consumption (3.6 M€), gross margin stands at 7.9 M€, i.e. a rate of 68%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 3.0 M€, representing 25.5% of revenue. Positive scissor effect: EBITDA margin improves by +4.7 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2.2 M€, i.e. 18.9% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

11 564 354 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

7 917 869 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

2 953 328 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

2 759 642 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

2 182 582 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

25.5%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 7%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 75%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 19.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

7.205%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

75.478%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

19.403%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.118

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

8.6%

Solvency indicators evolution
MEDICOS ROMBACH

Sector positioning

Debt ratio
7.21 2024
2022
2023
2024
Q1: 0.81
Med: 21.34
Q3: 62.69
Good -16 pts over 3 years

In 2024, the debt ratio of MEDICOS ROMBACH (7.21) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
75.48% 2024
2022
2023
2024
Q1: 34.69%
Med: 51.42%
Q3: 66.21%
Excellent +9 pts over 3 years

In 2024, the financial autonomy of MEDICOS ROMBACH (75.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.12 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.67 years
Q3: 2.23 years
Good -28 pts over 3 years

In 2024, the repayment capacity of MEDICOS ROMBACH (0.12) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 468.52. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.3x. Danger: operating income does not cover interest charges, unsustainable situation.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

468.518

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.291

Liquidity indicators evolution
MEDICOS ROMBACH

Sector positioning

Liquidity ratio
468.52 2024
2022
2023
2024
Q1: 149.84
Med: 223.59
Q3: 339.99
Excellent

In 2024, the liquidity ratio of MEDICOS ROMBACH (468.52) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
0.29x 2024
2022
2023
2024
Q1: 0.29x
Med: 3.95x
Q3: 10.02x
Average

In 2024, the interest coverage of MEDICOS ROMBACH (0.3x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 28 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 28 days. Inventory turnover is 53 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 74 days of revenue, i.e. 2.4 M€ to permanently finance. Notable WCR improvement over the period (-34%), freeing up cash.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

2 361 441 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

28 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

28 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

53 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

74 j

WCR and payment terms evolution
MEDICOS ROMBACH

Positioning of MEDICOS ROMBACH in its sector

Comparison with sector Fabrication d'emballages en matières plastiques

Valuation estimate

Based on 76 transactions of similar company sales (all years), the value of MEDICOS ROMBACH is estimated at 3 327 200 € (range 1 316 251€ - 8 054 174€). With an EBITDA of 2 953 328€, the sector multiple of 1.3x is applied. The price/revenue ratio is 0.20x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
76 tx
1316k€ 3327k€ 8054k€
3 327 200 € Range: 1 316 251€ - 8 054 174€
NAF 4 all-time Aggregated at NAF sub-class level

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
2 953 328 € × 1.3x
Estimation 3 729 679 €
1 487 712€ - 8 280 720€
Revenue Multiple 30%
11 564 354 € × 0.20x
Estimation 2 352 734 €
1 124 722€ - 3 166 201€
Net Income Multiple 20%
2 182 582 € × 1.7x
Estimation 3 782 703 €
1 174 896€ - 14 819 773€
How is this estimate calculated?

This estimate is based on the analysis of 76 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fabrication d'emballages en matières plastiques)

Compare MEDICOS ROMBACH with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication d'emballages en matières plastiques

Frequently asked questions about MEDICOS ROMBACH

What is the revenue of MEDICOS ROMBACH ?

The revenue of MEDICOS ROMBACH in 2024 is 11.6 M€.

Is MEDICOS ROMBACH profitable?

Yes, MEDICOS ROMBACH generated a net profit of 2.2 M€ in 2024.

Where is the headquarters of MEDICOS ROMBACH ?

The headquarters of MEDICOS ROMBACH is located in ROMBACH-LE-FRANC (68660), in the department Haut-Rhin.

Where to find the tax return of MEDICOS ROMBACH ?

The tax return of MEDICOS ROMBACH is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does MEDICOS ROMBACH operate?

MEDICOS ROMBACH operates in the sector Fabrication d'emballages en matières plastiques (NAF code 22.22Z). See the 'Sector positioning' section above to compare the company with its competitors.